The human mucin MUC1 is being investigated to determine its function and potential for use as a target antigen for different immunodiagnostic and immunotherapeutic protocols for diagnosing and treating pancreatic, breast, ovarian, and lung adenocarcinomas. Many of the tumor associated epitopes found on MUC1, which can include both carbohydrate and protein epitopes, are distinct among adenocarcinomas from different organ sites. These tumor antigens result from differential glycosylation of the core protein in different normal tissues and tumors derived from them. The types of complex oligosaccharides that can be added to MUC1 include those that are found on the family of cell surface adhesion molecules known as selectins and selectin ligands. MUC1 has several structural features deduced from primary amino acid sequence that are similar to selectin ligands. It is possible that some of these have biological functions as cell surface adhesion molecules for the tumor cells, or that secreted, soluble, glycoforms of MUC1 produced by some adenocarcinomas affect the cell trafficking patterns of lymphoid and inflammatory cells in patients with these malignancies. An epitope tagged MUC1 construct has have been developed and presents a unique opportunity to use MUC1 as a paradigm to study the relationship between its primary amino acid sequence its post- translational processing. The hypothesis being tested is that elements in the primary amino acid sequence of MUC1 contribute to its unique post- translational processing by secretory epithelial cells. The biological effects (molecular, morphological, and functional) of introducing mutations in the MUC1 sequence will also be evaluated. The proposed studies are designed to investigate: the types of oligosaccharides attached to MUC1 and their positions of attachment; the processes whereby the secreted and membrane bound forms of MUC1 are produced; the relative contribution of primary amino acid sequence to trafficking patterns, glycosylation, recycling secretion, and function; whether MUC1 plays a functional role in the metastatic properties of human adenocarcinomas.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA057362-06
Application #
2683526
Study Section
Pathology B Study Section (PTHB)
Program Officer
Mohla, Suresh
Project Start
1992-09-01
Project End
2000-03-31
Budget Start
1998-04-01
Budget End
1999-03-31
Support Year
6
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Nebraska Medical Center
Department
Type
Schools of Medicine
DUNS #
City
Omaha
State
NE
Country
United States
Zip Code
68198
Fink, Darci M; Steele, Maria M; Hollingsworth, Michael A (2016) The lymphatic system and pancreatic cancer. Cancer Lett 381:217-36
Hanson, Ryan L; Brown, Roger B; Steele, Maria M et al. (2016) Identification of FRA-1 as a novel player in pancreatic cancer in cooperation with a MUC1: ERK signaling axis. Oncotarget 7:39996-40011
Liu, X; Caffrey, T C; Steele, M M et al. (2014) MUC1 regulates cyclin D1 gene expression through p120 catenin and ?-catenin. Oncogenesis 3:e107
Liu, Xiang; Huang, Huocong; Remmers, Neeley et al. (2014) Loss of E-cadherin and epithelial to mesenchymal transition is not required for cell motility in tissues or for metastasis. Tissue Barriers 2:e969112
Thege, Fredrik I; Lannin, Timothy B; Saha, Trisha N et al. (2014) Microfluidic immunocapture of circulating pancreatic cells using parallel EpCAM and MUC1 capture: characterization, optimization and downstream analysis. Lab Chip 14:1775-84
Radhakrishnan, Prakash; Dabelsteen, Sally; Madsen, Frey Brus et al. (2014) Immature truncated O-glycophenotype of cancer directly induces oncogenic features. Proc Natl Acad Sci U S A 111:E4066-75
Liu, Xiang; Yi, Chunhui; Wen, Yunfei et al. (2014) Interactions between MUC1 and p120 catenin regulate dynamic features of cell adhesion, motility, and metastasis. Cancer Res 74:1609-20
Remmers, Neeley; Anderson, Judy M; Linde, Erin M et al. (2013) Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer. Clin Cancer Res 19:1981-93
Radhakrishnan, Prakash; Grandgenett, Paul M; Mohr, Ashley M et al. (2013) Expression of core 3 synthase in human pancreatic cancer cells suppresses tumor growth and metastasis. Int J Cancer 133:2824-33
Radhakrishnan, Prakash; Mohr, Ashley M; Grandgenett, Paul M et al. (2013) MicroRNA-200c modulates the expression of MUC4 and MUC16 by directly targeting their coding sequences in human pancreatic cancer. PLoS One 8:e73356

Showing the most recent 10 out of 59 publications